TAKEDA PHARMACEUTICAL CO LTD ADR (NYSE: TAK)

TAKEDA PHARMACEUTICAL CO LTD ADR

NYSE: TAK (Takeda Pharmaceutical Company L)

最近更新时间: 28 Nov, 5:34AM

14.52

0.02 (0.14%)

加入群组

前收盘价格	14.50
收盘价格	14.51
成交量	2,121,905
平均成交量 (3个月)	2,975,236
市值	48,318,943,232

市盈率 (P/E TTM)	207.43
预期市盈率 (P/E Forward)	9.58
价格/销量 (P/S)	1.64
股市价格/股市净资产 (P/B)	1.00

52周波幅	12.80 (-11%) — 15.69 (8%)
利润日期	29 Jan 2026
股息率 (DY TTM)	4.61%

市场趋势

		短期	中期
行业	Drug Manufacturers - Specialty & Generic (US)	看涨	混合的
	Drug Manufacturers - Specialty & Generic (全球的)	看涨	混合的
股票	Takeda Pharmaceutical Company L	混合的	混合的

AIStockmoo 评分

1.4

分析师共识	2.0
内部交易活动	NA
价格波动	-1.0
技术平均移动指标	2.5
技术振荡指标	2.0
平均	1.38

相关股票

股票	市值	DY	P/E（TTM）	P/B
TAK	48 B	4.61%	207.43	1.00
ZTS	53 B	0.83%	20.21	10.46
HLN	44 B	1.20%	22.18	2.06
RDY	12 B	54.73%	17.71	2.89
TEVA	31 B	-	44.08	4.23
BHC	2 B	-	23.46	-

Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
部门	Healthcare
行业	Drug Manufacturers - Specialty & Generic
投资方式	Large Core
内部持股比例	0.01%
机构持股比例	2.30%

该时间范围内无数据。

日期	类型	细节
07 Nov 2025	公告	Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
03 Nov 2025	公告	New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
30 Oct 2025	公告	Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
27 Oct 2025	公告	HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
21 Oct 2025	公告	Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
21 Oct 2025	公告	HEALWELL's DARWEN(TM) AI Platform Demonstrates One of the World's First Examples of Using AI to Generate Regulatory-Grade Real-World Data (RWD) for Supporting Patient Access and Advancing the Pharmaceutical Industry
23 Sep 2025	公告	20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
16 Sep 2025	公告	Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
11 Sep 2025	公告	Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
08 Sep 2025	公告	Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
05 Sep 2025	公告	U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
显示更多

股息率 (DY TTM)	4.61%
5年平均股息收益率	3.39%
股息支付比率	289.45%

除息日	公告日期	支付日期	详情
30 Mar 2023	15 Mar 2023	10 Jul 2023	0.30996 现金
29 Sep 2022	13 Sep 2022	12 Dec 2022	0.329553 现金
30 Mar 2022	04 Mar 2022	11 Jul 2022	0.330062 现金
29 Sep 2021	-	13 Dec 2021	0.396898 现金
30 Mar 2021	15 Mar 2021	12 Jul 2021	0.406627 现金
29 Sep 2020	-	11 Dec 2020	0.430533 现金
30 Mar 2020	-	06 Jul 2020	0.419053 现金
27 Sep 2019	09 Sep 2019	12 Dec 2019	0.411118 现金
28 Mar 2019	16 Mar 2019	10 Jul 2019	0.417168 现金
26 Sep 2018	-	13 Dec 2018	0.395501 现金
27 Mar 2018	-	09 Jul 2018	0.40643 现金
27 Sep 2017	-	11 Dec 2017	0.39946 现金
29 Mar 2017	-	10 Jul 2017	0.39892 现金
28 Sep 2016	-	12 Dec 2016	0.392415 现金
29 Mar 2016	-	11 Jul 2016	0.43705 现金
28 Sep 2015	-	11 Dec 2015	0.365323 现金
27 Mar 2015	-	09 Jul 2015	0.365289 现金
25 Sep 2014	-	11 Dec 2014	0.378342 现金
26 Mar 2014	-	10 Jul 2014	0.443655 现金
25 Sep 2013	-	12 Dec 2013	0.436978 现金
26 Mar 2013	-	08 Jul 2013	0.457131 现金
25 Sep 2012	-	13 Dec 2012	0.545983 现金
27 Mar 2012	-	09 Jul 2012	0.563768 现金
27 Sep 2011	-	12 Dec 2011	0.578629 现金
28 Mar 2011	-	07 Jul 2011	0.555761 现金
27 Sep 2010	-	13 Dec 2010	0.533229 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2023	0.310	1	2.17
2022	0.660	2	4.23
2021	0.804	2	5.90
2020	0.850	2	4.67
2019	0.828	2	4.20
2018	0.802	2	4.77
2017	0.798	2	2.81
2016	0.829	2	3.99
2015	0.731	2	2.92
2014	0.822	2	3.96
2013	0.894	2	3.88
2012	1.11	2	5.00
2011	1.13	2	5.15
2010	0.533	1	2.19
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2025	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	2.36%
营业利益率 (TTM)	11.68%
稀释每股收益 (EPS TTM)	0.230
季度收入增长率 (YOY)	0.20%
季度盈利增长率 (YOY)	-77.50%

总债务/股东权益 (D/E MRQ)	73.36%
流动比率 (MRQ)	1.01
营业现金流 (OCF TTM)	1.06 T
杠杆自由现金流 (LFCF TTM)	735.62 B

资产报酬率 (ROA TTM)	2.40%
股东权益报酬率 (ROE TTM)	1.52%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)